This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

TechAtlas Group Releases Type 1 Diabetes Competitive Landscape Analysis

BOSTON, Sept. 6, 2013 /PRNewswire/ -- TechAtlas Group has announced the release of the latest Type 1 Diabetes (T1DM) competitive landscape map. This particular landscape highlights 71 international companies with over 140 drugs and devices currently on the market and in development.

(Logo: )

Topics include:
  • Save the cells: immune therapies for T1DM
  • Beta-cell regeneration strategies
  • Pancreatic replacement via cell-based therapy
  • Therapeutic considerations: childhood, adolescence, adulthood & older adults
  • Managing hypoglycemia: new pens and bi-hormonal systems
  • Competitive positioning in the insulin market
  • Non-insulin add-on therapies for tighter glycemic control
  • Strategic implications of artificial pancreas development

TechAtlas' analysts have evaluated each clinical asset according to the parameters that dictate their commercial competitiveness, including clinical benefit/risk, cost, patient preference, and reimbursement dynamics. For example, competition in this field is driving the creation of longer-lasting (7+ days use), slimmer CGMs to increase patient acceptance. However, the need for frequent finger-stick blood glucose calibrations presents a critical obstacle to CGM use, which will only be resolved by significant technical advances that lower the mean absolute relative difference (MARD) of the CGMs. Meanwhile, new stable glucagon formulations are laying the foundation for better hypoglycemic control by facilitating simpler rescue pen systems and, more importantly, bi-hormonal delivery pumps that will contribute to the "holy grail" – a fully independent artificial pancreas system.

The TechAtlas map graphically presents every T1DM-related technology, old and new, in its proper context to clearly show the relationship of competing and complementary products for specific unmet needs and ideal treatment paradigms like T1DM prevention and development of the artificial pancreas. This map was built on extensive primary research, including interviews with companies, investors, key opinion leaders in the diabetes community, academic researchers, technical experts, consumers of technologies, and other stakeholders in the field, as well as an exhaustive review of public and proprietary resources.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs